Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Bob Holland


Bob Holland has joined Oxford Gene Technology as its chief medical officer.

Holland previously served as vice president and head of AstraZeneca's Personalized Healthcare and Biomarkers division.

In his new role at OGT, Holland will lead clinical affairs across OGT's business areas. He will work with the UK company's R&D and commercial teams to develop clinical development programs that will expand its next-generation sequencing and microarray cancer profiling solutions. Holland will also work with OGT's biomarker programs for prostate and colorectal cancers, OGT said.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.